Research

From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

By Bill Snyder
July 16, 2021

Study identifies monoclonal antibodies that may neutralize many norovirus variants

Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

By Bill Snyder
July 15, 2021

Arterial stiffening linked to Alzheimer’s disease

A research team from Vanderbilt University Medical Center reports in Neurology that greater stiffening of the aorta, the main artery in the human body, is associated in older adults with increased Alzheimer’s disease (AD) pathology as reflected in a range of neurochemical indicators measured in cerebrospinal fluid.

By Paul Govern
From left, MacRae Linton, MD, Huan Tao, MD, PhD, Jonathan Brown, MD, and colleagues have discovered a potential new target for preventing atherosclerosis.
July 8, 2021

Nature’s “recycler” could reduce heart disease risk: study

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

By Bill Snyder
July 8, 2021

Study finds genetic risk factors for severe COVID-19 illness

A massive worldwide collaboration including researchers from Vanderbilt University Medical Center (VUMC) has identified several genetic factors associated with SARS-CoV-2 infection and severe COVID-19 illness.

By Bill Snyder
July 7, 2021

Nobel laureate Doudna set for next Discovery Lecture

Nobel laureate Jennifer Doudna, PhD, winner of the 2020 Vanderbilt Prize in Biomedical Science, will deliver the next web-based Discovery Lecture on Thursday, July 22.

By Bill Snyder
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
By Tom Wilemon
June 17, 2021

Drug allergy labels in medical records power searches for gene-drug associations

By Paul Govern
June 3, 2021

VUMC team discovers new genetic disease

Researchers at Vanderbilt University Medical Center have discovered a new genetic disease that causes a severe form of neurogenic orthostatic hypotension, a rapid drop in blood pressure upon standing that can cause fainting.
By Bill Snyder
June 3, 2021

Predictive model identifies patients for genetic testing

Patients who, perhaps unbeknownst to their health care providers, are in need of genetic testing for rare undiagnosed diseases can be identified en masse based on routine information in electronic health records (EHRs), a research team reported June 3 in the journal Nature Medicine.
By Paul Govern
May 13, 2021

People at high genetic risk for colorectal cancer benefit more from lifestyle changes

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.
By Tom Wilemon
May 12, 2021

Nominations sought for Vanderbilt Prize Student Scholar

Nominations for the 2021 Vanderbilt Prize Student Scholar are now open. The deadline is June 1.
By Bill Snyder
May 6, 2021

VUMC to lead national study to treat severe COVID complications

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.
By Bill Snyder